摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[4-(2-(1-adamantyl)-6-methoxy-8-quinolylamino)pentyl]-1,3-isoindolinedione | 762301-53-1

中文名称
——
中文别名
——
英文名称
2-[4-(2-(1-adamantyl)-6-methoxy-8-quinolylamino)pentyl]-1,3-isoindolinedione
英文别名
2-[4-(2-adamantyl-6-methoxy-8-quinolylamino)pentyl]-1,3-isoindolinedione;2-[4-[[2-(1-Adamantyl)-6-methoxyquinolin-8-yl]amino]pentyl]isoindole-1,3-dione
2-[4-(2-(1-adamantyl)-6-methoxy-8-quinolylamino)pentyl]-1,3-isoindolinedione化学式
CAS
762301-53-1
化学式
C33H37N3O3
mdl
——
分子量
523.675
InChiKey
BOSYHWYSHOPEJW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.9
  • 重原子数:
    39
  • 可旋转键数:
    8
  • 环数:
    8.0
  • sp3杂化的碳原子比例:
    0.48
  • 拓扑面积:
    71.5
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Discovery of a Bulky 2-tert-Butyl Group Containing Primaquine Analogue That Exhibits Potent Blood-Schizontocidal Antimalarial Activities and Complete Elimination of Methemoglobin Toxicity
    摘要:
    To eliminate an unwarranted metabolic pathway of the quinoline ring, a set of two compounds, where C-2 position of the antimalarial drug primaquine is blocked by metabolically stable bulky alkyl group are synthesized. Compound 2 [R = C(CH3)(3)] of the series has produced excellent antimalarial efficacy against P. berghei and highly virulent multidrug-resistant P. yoelii nigeriensis strain in vivo. Compound 2 was also evaluated for methemoglobin (MetHb) toxicity. This study describes the discovery of a highly potent blood-schizontocidal antimalarial analogue 2, completely devoid of MetHb toxicity.
    DOI:
    10.1021/jm0304562
  • 作为产物:
    描述:
    1-金刚烷甲酸 ammonium persulfate 、 硫酸氢气silver nitrate三乙胺 作用下, 以 乙醇乙腈 为溶剂, 120.0 ℃ 、310.26 kPa 条件下, 反应 24.92h, 生成 2-[4-(2-(1-adamantyl)-6-methoxy-8-quinolylamino)pentyl]-1,3-isoindolinedione
    参考文献:
    名称:
    Discovery of a Bulky 2-tert-Butyl Group Containing Primaquine Analogue That Exhibits Potent Blood-Schizontocidal Antimalarial Activities and Complete Elimination of Methemoglobin Toxicity
    摘要:
    To eliminate an unwarranted metabolic pathway of the quinoline ring, a set of two compounds, where C-2 position of the antimalarial drug primaquine is blocked by metabolically stable bulky alkyl group are synthesized. Compound 2 [R = C(CH3)(3)] of the series has produced excellent antimalarial efficacy against P. berghei and highly virulent multidrug-resistant P. yoelii nigeriensis strain in vivo. Compound 2 was also evaluated for methemoglobin (MetHb) toxicity. This study describes the discovery of a highly potent blood-schizontocidal antimalarial analogue 2, completely devoid of MetHb toxicity.
    DOI:
    10.1021/jm0304562
点击查看最新优质反应信息

文献信息

  • Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents
    申请人:——
    公开号:US20040192724A1
    公开(公告)日:2004-09-30
    The present invention is concerned with the development of novel 8-aminoquinoline analogs in the treatment and prevention of malaria and the said compound has broad spectrum of activity against the blood as well as tissue stages of the human malaria parasites makes these compounds very attractive in the cure and prevention of malaria caused by drug-sensitive and multidrug resistant strains and also it is expected that development of these compounds as ideal antimalarial agents may lead to suppression as well as radical cure of the malaria infection with single drug therapy.
    本发明涉及新型8-氨基喹啉类似物在治疗和预防疟疾方面的开发,所述化合物对人类疟原虫的血期及组织期具有广谱活性,使得这些化合物在治疗和预防由药物敏感和多药耐药菌株引起的疟疾方面极具吸引力。同时,预期将这些化合物开发为理想的抗疟药物可能会导致单一药物疗法既能抑制又能根治疟疾感染。
  • Methods and compositions for the treatment of neurodegenerative disorders
    申请人:Jin Xiaowei
    公开号:US20080044390A1
    公开(公告)日:2008-02-21
    The present invention features compositions, kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease.
  • US6979740B2
    申请人:——
    公开号:US6979740B2
    公开(公告)日:2005-12-27
查看更多